Esketamine Receives Support from 2 FDA Committees

Esketamine, a drug developed by Johnson & Johnson for the treatment of depression has received support from two FDA committees. Final FDA approval is expected by March 2019. The drug has been approved for use in treatment resistant depression. From the...